Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immune Checkpoint Therapy;Adoptive Cell Therapy
Treatment anti-PD-1
Drugstatus NA
Drugbank ID NA
Checkpoints PD-1
Signature Type Gene
Signature CCL4
Official Symbol CCL4
Mode of action TRAN_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Mouse model
Description Expression of Ccl3 and Ccl4, involved in NK cell migration via CCR5 recognition, more than doubled
PMID 29339375
Title TUSC2 immunogene therapy synergizes with anti–PD-1 through enhanced proliferation and infiltration of natural killer cells in syngeneic Kras-mutant mouse lung cancer models